In vivo, an anti-CXCR3 antibody reversed the suppression of GBM growth seen in the EMP3_KO group but further promoted tumorigenesis in the EMP3_Scra group and led to poor survival (Fig. 5d-f). This evidence concerns the gene CXCR3 and glioblastoma.